Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans
Joseph H Poetsch, Christine Dahlke, Madeleine E Zinser, Rahel Kasonta, Sebastian Lunemann, Anne Rechtien, My L Ly, Hans C Stubbe, Verena Krähling, Nadine Biedenkopf, Markus Eickmann, Sarah K Fehling, Flaminia Olearo, Thomas Strecker, Piyush Sharma, Karl S Lang, Ansgar W Lohse, Stefan Schmiedel, Stephan Becker, VSV-Ebola Consortium (VEBCON), Marylyn M Addo, Claire-Anne Siegrist, Angela Huttner, Marylyn M Addo, Stephan Becker, Verena Krähling, Phillip Bejon, Patricia Njuguna, Francis Ndungu, Peter G Kremsner, Jessica S Brosnahan, Selidji Todagbe Agnandji, Sanjeev Krishna, Marie Paule Kieny, Kayvon Modjarrad, Vasee Moorthy, Patricia Fast, Barbara Savarese, Olivier Lapujade, Joseph H Poetsch, Christine Dahlke, Madeleine E Zinser, Rahel Kasonta, Sebastian Lunemann, Anne Rechtien, My L Ly, Hans C Stubbe, Verena Krähling, Nadine Biedenkopf, Markus Eickmann, Sarah K Fehling, Flaminia Olearo, Thomas Strecker, Piyush Sharma, Karl S Lang, Ansgar W Lohse, Stefan Schmiedel, Stephan Becker, VSV-Ebola Consortium (VEBCON), Marylyn M Addo, Claire-Anne Siegrist, Angela Huttner, Marylyn M Addo, Stephan Becker, Verena Krähling, Phillip Bejon, Patricia Njuguna, Francis Ndungu, Peter G Kremsner, Jessica S Brosnahan, Selidji Todagbe Agnandji, Sanjeev Krishna, Marie Paule Kieny, Kayvon Modjarrad, Vasee Moorthy, Patricia Fast, Barbara Savarese, Olivier Lapujade
Abstract
In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099). A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonstrated clinical efficacy. While EBOV-specific immune responses to this candidate vaccine have previously been investigated, limited human data on immunity to the VSV vector are available. Within the scope of a phase 1 study, we performed a comprehensive longitudinal analysis of adaptive immune responses to internal VSV proteins following VSV-EBOV immunization. While no preexisting immunity to the vector was observed, more than one-third of subjects developed VSV-specific cytotoxic T-lymphocyte responses and antibodies.
Figures
References
- Agnandji ST, Huttner A, Zinser ME, et al. . Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374:1647–60.
- Coller BG, Blue J, Das R, et al. . Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine 2017; 35:4465–9.
- Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204(Suppl 3):S1075–81.
- Marzi A, Robertson SJ, Haddock E, et al. . Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015; 349:739–42.
- Henao-Restrepo AM, Longini IM, Egger M, et al. . Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857–66.
- Zhu FC, Hou LH, Li JX, et al. . Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 2015; 385:2272–9.
- Bukreyev A, Marzi A, Feldmann F, et al. . Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009; 383:348–61.
- Dahlke C, Kasonta R, Lunemann S, et al. . VEBCON Consortium Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization. EBioMedicine 2017; 19:107–18.
- Medaglini D, Santoro F, Siegrist CA. Correlates of vaccine-induced protective immunity against Ebola virus disease. Semin Immunol 2018. doi:10.1016/j.smim.2018.07.003.
- Li SS, Kochar NK, Elizaga M, et al. . DNA priming increases frequency of T-cell responses to a vesicular stomatitis virus HIV vaccine with specific enhancement of CD8(+) T-cell responses by interleukin-12 plasmid DNA. Clin Vaccine Immunol 2017; 24. doi:10.1128/CVI.00263-17.
- Harrington LE, Most Rv Rv, Whitton JL, Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002; 76:3329–37.
- Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT Jr, Beigel JH. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med 2016; 22:1439–47.
- Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis 2015; 21:305–7.
- Monath TP, Gershman M, Staples JE. Yellow fever vaccine. In: Plotkin SA Orenstein WA, Offit PA, eds. Vaccines. 6th ed. London: W.B. Saunders, 2013: 870–968.
- Furman D, et al. . Cytomegalovirus infection improves immune responses to influenza. Sci Transl Med 2015; 7:281ra43.
Source: PubMed